ACCP Clinical Reasoning Series in Pharmacotherapy, Home Study Edition Recorded Lecture, CE 2025 (Videos + Audios + Slides)

ACCP’s 2025 Clinical Reasoning Series in Pharmacotherapy uses focused therapeutic problems to support case-based medication decisions. The home-study program comprises three activities: oncology immunotherapy, pulmonary care, and antithrombotic and lipid management. Subjects include recognizing treatment-related toxicities, differentiating asthma and COPD, evaluating antiplatelet choices around acute coronary syndromes, and assessing cardiovascular risk. The cardiovascular activity contains separate antithrombotic and lipid-focused presentations. This listing provides videos, audio, and slides for clinical pharmacists who want to revisit the lectures and supporting material. The original learning objectives, supplied Topics list, and faculty details appear below without repeated promotional summaries.

Package: Videos + Audios + Slides. The original activities are listed as 1.50 hours for oncology, 1.50 hours for pulmonary care, and 3.00 hours for antithrombotic and lipid management. Official ACCP participation and posttests are separate; these files do not provide CPE or BCPS recertification credit.

Updates, Safety, and Management of Immune Checkpoint Inhibitor and Immune Effector Cell Therapies

Learning Objectives

Participants should be able to:

• Compare mechanisms and indications of immune checkpoint inhibitor and immune effector cell therapies.
• Recognize the clinical presentation of immune checkpoint inhibitor-related toxicities.
• Design therapeutic monitoring plans for immune checkpoint inhibitor therapy.
• Differentiate cytokine release syndrome (CRS) from immune effector cell-associated neurotoxicity syndrome (ICANS).
• Develop management strategies for toxicities associated with immune effector cell therapy.

Integrating Medication Management into Practice

Learning Objectives

Participants should be able to:

• Differentiate the clinical features and management approaches of asthma, COPD, and asthma-COPD overlap.
• Review newly approved and emerging therapies for asthma and COPD.
• Incorporate current guideline-recommended immunizations into comprehensive pulmonary care.
• Evaluate the potential benefits of weight-loss treatment in patients with obesity and obstructive sleep apnea.
• Design individualized treatment plans for patients with overlapping pulmonary conditions.

What A Thrill! Launching Into Peri-ACS Antithrombotic Therapies

Learning Objectives

Participants should be able to:

• Distinguish among available antiplatelet options for acute coronary syndromes.
• Evaluate upstream antiplatelet administration timing in NSTE-ACS.
• Apply ischemic and bleeding risk scoring tools.
• Choose individualized dosing strategies for specific patient scenarios.

Catching the Wave of Integrated Care: Predictive Models and Emerging Therapies in Cardiovascular Risk Management

Learning Objectives

Participants should be able to:

• Develop comprehensive care plans integrating cardiovascular, kidney, and metabolic treatment targets.
• Compare factors influencing cardiovascular risk estimation using pooled cohort equations and PREVENT.
• Apply coronary artery calcium recommendations to clinical decision-making.
• Evaluate emerging treatments targeting Lipoprotein(a) in high-risk patients.

+ Topics:

• 01 Oncology Pharmacotherapy – Contemporary Clinical Reasoning for Cancer Medication Therapy, Monitoring, Safety, and Patient-Specific Treatment
• 02 Immune Checkpoint Inhibitors – Mechanisms, Indications, Monitoring, and Recognition of Immune-Related Adverse Events
• 03 Immune Effector Cell Therapy – Clinical Use, Therapeutic Monitoring, and Management of Treatment-Related Complications
• 04 Cytokine Release Syndrome – Recognition, Differentiation, Severity Assessment, and Management of CRS After Immune Effector Cell Therapy
• 05 ICANS Neurotoxicity – Identifying and Managing Immune Effector Cell-Associated Neurotoxicity Syndrome
• 06 Immunotherapy Medication Safety – Monitoring Organ Toxicity, Adverse Events, and Treatment-Related Complications in Oncology Patients
• 07 Asthma Pharmacotherapy – Clinical Differentiation, Updated Treatment Options, Biologic Therapy, and Individualized Medication Management
• 08 COPD Pharmacotherapy – Contemporary Medication Selection, Emerging Therapies, Monitoring, and Patient-Centered Treatment
• 09 Asthma-COPD Overlap – Identifying Overlapping Clinical Features and Developing Individualized Pharmacotherapy Strategies
• 10 Severe Pulmonary Disease – Integrating Biologic Agents and Emerging Therapies Into Asthma and COPD Management
• 11 Pulmonary Immunization Strategies – Incorporating Current Vaccination Recommendations Into Comprehensive Respiratory Care
• 12 Obesity and Obstructive Sleep Apnea – Evaluating Weight-Loss Treatment as Part of Integrated Sleep-Related Pulmonary Care
• 13 Acute Coronary Syndrome Pharmacotherapy – Evidence-Based Antiplatelet Selection and Medication Management in ACS
• 14 NSTE-ACS Antiplatelet Strategies – Timing, Dosing, Upstream Therapy, and Patient-Specific Treatment Decisions
• 15 Ischemic and Bleeding Risk – Applying Clinical Risk Scores to Balance Cardiovascular Protection and Medication Safety
• 16 Peri-Procedural Antithrombotic Therapy – Medication Transitions, Therapeutic Monitoring, and Individualized Management Around Procedures
• 17 Cardiovascular Risk Assessment – Comparing Pooled Cohort Equations With the PREVENT Cardiovascular Risk Model
• 18 Coronary Artery Calcium – Applying CAC Guidance to Refine Cardiovascular Risk and Lipid-Treatment Decisions
• 19 Statin Therapy and Lipid Management – Patient Selection, Risk-Based Treatment Decisions, and Contemporary Dyslipidemia Pharmacotherapy
• 20 Lipoprotein(a) – Emerging Therapeutic Strategies for Residual Cardiovascular Risk Reduction in High-Risk Patients
• 21 Cardiovascular-Kidney-Metabolic Care – Integrating Cardiovascular, Renal, and Metabolic Treatment Targets in Complex Patients
• 22 Emerging Lipid-Lowering Therapies – Novel Pharmacologic Approaches and Their Potential Role in Cardiovascular Event Prevention
• 23 Clinical Evidence Evaluation – Critically Appraising Contemporary Therapeutic Literature and Applying Findings to Practice
• 24 Medication Monitoring and Safety – Designing Patient-Specific Monitoring Plans Across Oncology, Pulmonary, and Cardiovascular Therapy
• 25 BCPS Clinical Reasoning – Translating Scientific Evidence Into Safe, Effective, Individualized Pharmacotherapy Decisions

Program Chair

Alyssa Robertson, Pharm.D., BCCCP, BCEMP, BCPS

Clinical Pharmacist Specialist – Emergency Medicine
WellSpan York Hospital
York, Pennsylvania

Faculty

Lauren Ice, Pharm.D., BCOP, BCPS

Pharmacy Supervisor, Cancer Health & Transplant
Corewell Health
Grand Rapids, Michigan

Jessica L. Wallace, Pharm.D., BCPS

Associate Professor
Lipscomb University College of Pharmacy

Clinical Pharmacy Specialist
Veterans Affairs Tennessee Valley Healthcare System / Vanderbilt University Medical Center
Nashville, Tennessee

Amanda G. Sowder, Pharm.D., BCCP

Interventional Cardiology & Electrophysiology Laboratory Pharmacist
AdventHealth Orlando

Maria C. Coyle, Pharm.D., B.S.Pharm, FCCP, BCACP, BCPS, CLS

Professor – Clinical
The Ohio State University College of Pharmacy

Specialty Pharmacist – Ambulatory
The Ohio State University Wexner Medical Center
Columbus, Ohio

File scope: The purchase covers the educational files offered by MedicalAmboss. It does not include event registration, live participation, publisher-platform access, accounts, memberships, or publisher-hosted extras.